已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Liver Resection and Transplantation in the Era of Checkpoint Inhibitors

肝移植 医学 切除术 移植 肿瘤科 癌症研究 内科学 外科
作者
Parissa Tabrizian,Rebecca Marino,Pierce K. H. Chow
出处
期刊:JHEP reports [Elsevier BV]
卷期号:6 (11): 101181-101181 被引量:1
标识
DOI:10.1016/j.jhepr.2024.101181
摘要

Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape for advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab has demonstrated efficacy, establishing a new standard of care for advanced HCC. Neoadjuvant studies have shown promising results with high response rates, increasing research into ICIs' role. In the peri-operative setting, in addition to adjuvant and neo-adjuvant therapies, strategies for "downstaging" and "bridging" patients to liver transplantation (LT) are being investigated, broadening the eligible candidate pool. Furthermore, therapeutic advances have reshaped conversion strategies for hepatic resection, with emerging evidence indicating a role for adjuvant immunotherapy in patients at high risk of postoperative recurrence. In LT, concerns have arisen over the potential conflict between immunosuppression needs and the immune-enhancing effects of ICIs, with reports of severe rejection. However, liver-specific factors may lessen rejection risks, prompting exploration into the safety of pre-transplant ICI administration. Moreover, ongoing trials must prioritise patient selection and vigilant management protocols. Despite the remarkable progress in immunotherapy, the intricate molecular interactions within the tumour microenvironment and their implications on oncogenic pathways remain incompletely understood. This highlights the need for specialised expertise to effectively integrate immunotherapy into the surgical management of HCC. Key challenges include ensuring safety, optimising oncological outcomes, managing the risk of graft rejection in transplant recipients, and refining patient selection criteria. In this review, we aim to provide a comprehensive overview of the evolving role of immunotherapy in the surgical management of HCC, discussing the rationale for its application in both pre- and post-surgical contexts, leveraging current clinical experience, identifying potential limitations, and envisioning future applications. By integrating existing knowledge and highlighting areas for further investigation, this review seeks to inform clinical practice and guide future research endeavours.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
郑博文完成签到,获得积分10
刚刚
1秒前
橘子屿布丁完成签到,获得积分10
1秒前
yanzu完成签到,获得积分0
2秒前
2秒前
李昶发布了新的文献求助10
2秒前
永恒完成签到 ,获得积分10
4秒前
华子的五A替身完成签到,获得积分10
4秒前
超级鸽子发布了新的文献求助200
5秒前
5秒前
懵懂的凝丹完成签到 ,获得积分10
6秒前
朴素板栗发布了新的文献求助10
7秒前
念姬完成签到 ,获得积分10
7秒前
聪慧不二完成签到 ,获得积分10
8秒前
香蕉觅云应助LYL采纳,获得10
8秒前
Hang完成签到,获得积分10
9秒前
brotherpeng完成签到 ,获得积分10
9秒前
威武的雨筠完成签到,获得积分10
9秒前
何吉民完成签到,获得积分10
10秒前
罐装发布了新的文献求助10
10秒前
11秒前
葡萄味的果茶完成签到 ,获得积分10
11秒前
舒适的方盒完成签到 ,获得积分10
12秒前
布丁完成签到 ,获得积分10
12秒前
Yi完成签到,获得积分10
12秒前
文艺鞋垫完成签到,获得积分10
12秒前
shentaii完成签到,获得积分10
12秒前
ZYY完成签到,获得积分10
13秒前
cxx完成签到 ,获得积分10
13秒前
无花果应助pear采纳,获得10
15秒前
不想搞科研完成签到,获得积分20
15秒前
lby完成签到 ,获得积分10
15秒前
隐形曼青应助开心的飞扬采纳,获得10
16秒前
小远完成签到 ,获得积分10
16秒前
dudulu完成签到,获得积分10
17秒前
超级小熊猫完成签到 ,获得积分10
17秒前
leeSongha完成签到 ,获得积分10
17秒前
木子完成签到 ,获得积分10
18秒前
礼岁岁完成签到 ,获得积分10
19秒前
机智若云完成签到,获得积分10
19秒前
高分求助中
All the Birds of the World 3000
Weirder than Sci-fi: Speculative Practice in Art and Finance 960
IZELTABART TAPATANSINE 500
Introduction to Comparative Public Administration: Administrative Systems and Reforms in Europe: Second Edition 2nd Edition 300
Spontaneous closure of a dural arteriovenous malformation 300
GNSS Applications in Earth and Space Observations 300
Not Equal : Towards an International Law of Finance 260
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3725140
求助须知:如何正确求助?哪些是违规求助? 3270248
关于积分的说明 9965180
捐赠科研通 2985226
什么是DOI,文献DOI怎么找? 1637832
邀请新用户注册赠送积分活动 777727
科研通“疑难数据库(出版商)”最低求助积分说明 747171

今日热心研友

蓝波酱
40
HEIKU
30
机灵柚子
10
洛洛大方
10
注:热心度 = 本日应助数 + 本日被采纳获取积分÷10